{"id":"https://openalex.org/W2556789334","doi":"https://doi.org/10.1182/blood.v116.21.2139.2139","title":"A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML","display_name":"A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML","publication_year":2010,"publication_date":"2010-11-19","ids":{"openalex":"https://openalex.org/W2556789334","doi":"https://doi.org/10.1182/blood.v116.21.2139.2139","mag":"2556789334"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v116.21.2139.2139","doi":"https://doi.org/10.1182/blood.v116.21.2139.2139","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.2139.2139","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051485142","display_name":"Sanjay Ram Mohan","orcid":"https://orcid.org/0000-0002-6715-6697","observed_orcids":["https://orcid.org/0000-0002-6715-6697"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay R. Mohan","raw_affiliation_strings":["Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA,","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085974329","display_name":"Jaroslaw Pawel Maciejewski","orcid":"https://orcid.org/0000-0002-6837-4346","observed_orcids":["https://orcid.org/0000-0002-6837-4346"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaroslaw P Maciejewski","raw_affiliation_strings":["Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA,","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002731684","display_name":"Bindu Tejura","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Bindu Tejura","raw_affiliation_strings":["Antisoma Inc, Cambridge, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma Inc, Cambridge, MA, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050556099","display_name":"Harry Paul Erba","orcid":"https://orcid.org/0000-0003-1093-2189","observed_orcids":["https://orcid.org/0000-0003-1093-2189"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]},{"id":"https://openalex.org/I4390039285","display_name":"U-M Rogel Cancer Center","ror":"https://ror.org/05asdy483","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445","https://openalex.org/I4390039285"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry P Erba","raw_affiliation_strings":["Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA,","institution_ids":["https://openalex.org/I27837315","https://openalex.org/I4390039285"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richard M Stone","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mikkael A. Sekeres","raw_affiliation_strings":["Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA,","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5002731684","https://openalex.org/A5071023119"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.3396693,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"116","issue":"21","first_page":"2139","last_page":"2139"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14078","display_name":"Multiple and Secondary Primary Cancers","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/secondary-acute-myeloid-leukemia","display_name":"secondary acute myeloid leukemia","score":0.9539999961853027},{"id":"https://openalex.org/keywords/treatment-related-acute-myeloid-leukemia","display_name":"treatment-related acute myeloid leukemia","score":0.8080000281333923},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.8330000042915344},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9480000138282776},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9909999966621399},{"id":"https://openalex.org/keywords/amonafide","display_name":"amonafide","score":0.8930000066757202},{"id":"https://openalex.org/keywords/cytogenetics","display_name":"cytogenetics","score":0.6660000085830688},{"id":"https://openalex.org/keywords/age-at-diagnosis","display_name":"age at diagnosis","score":0.5329999923706055},{"id":"https://openalex.org/keywords/male-sex","display_name":"male sex","score":0.5590000152587891},{"id":"https://openalex.org/keywords/white-blood-cell-count","display_name":"white blood cell count","score":0.7319999933242798},{"id":"https://openalex.org/keywords/bone-marrow-blasts","display_name":"bone marrow blasts","score":0.8159999847412109},{"id":"https://openalex.org/keywords/prior-chemotherapy","display_name":"prior chemotherapy","score":0.6480000019073486},{"id":"https://openalex.org/keywords/prior-radiotherapy","display_name":"prior radiotherapy","score":0.9509999752044678}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.8136060237884521},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6890169382095337},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6696900129318237},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6159545183181763},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5584262013435364},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.5583606362342834},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5533631443977356},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5133687257766724},{"id":"https://openalex.org/C144301174","wikidata":"https://www.wikidata.org/wiki/Q7893852","display_name":"Univariate analysis","level":3,"score":0.5113060474395752},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5067539811134338},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.43419912457466125},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.33583927154541016},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.26663634181022644},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.21629220247268677}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v116.21.2139.2139","doi":"https://doi.org/10.1182/blood.v116.21.2139.2139","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v116.21.2139.2139","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2980310295","https://openalex.org/W4381925250","https://openalex.org/W2536842264","https://openalex.org/W4386277476","https://openalex.org/W2065680405","https://openalex.org/W2597400660","https://openalex.org/W2244637987","https://openalex.org/W4385702320","https://openalex.org/W2580956723","https://openalex.org/W4292830471"],"abstract_inverted_index":{"Abstract":[0,1],"2139":[2],"Introduction:":[3],"Secondary":[4],"AML":[5,23,31,39,47],"(sAML),":[6],"a":[7,16,74,78,102,113,154,253,264,330],"well":[8],"recognized":[9],"poor":[10,45],"prognostic":[11,93,169,187,296,322,350],"factor":[12,188,297],"in":[13,95,153,300,309,354],"AML,":[14],"is":[15,101],"heterogeneous":[17],"group":[18],"of":[19,44,71,92,106,115,162,177,267,284,325,334,352,394],"diseases,":[20],"including":[21,109,374],"both":[22],"evolving":[24],"from":[25,73,123,175,339],"myelodysplastic":[26],"syndromes":[27],"(MDS,":[28,242],"MDS\u2192AML)":[29],"and":[30,77,88,120,140,142,193,199,263,318,345],"following":[32],"chemotherapy":[33,57,133,245],"for":[34,185,293],"another":[35],"malignancy,":[36],"i.e.":[37],"treatment-related":[38],"(tAML).":[40],"These":[41],"two":[42],"subtypes":[43],"risk":[46,369],"have":[48],"similar":[49],"outcomes":[50],"when":[51,358],"treated":[52,111,129,148],"with":[53,112,130,149,273,287,337,362,367],"the":[54,63,135,163,168,259,280,291,301,310,356],"same":[55,64],"cytarabine-based":[56,116,131],"regimen,":[58],"supporting":[59],"their":[60,194],"inclusion":[61],"into":[62],"clinical":[65],"category.":[66],"A":[67],"combined":[68,281,331],"data":[69,104,272,282,332],"set":[70,105,283,333],"patients":[72,108,110,128,147,286,336,361,366],"single":[75],"centre":[76],"phase":[79,155],"II":[80,156],"study":[81,157],"was":[82,165,256],"analyzed":[83],"to":[84,98,166],"determine":[85],"which":[86],"patient":[87],"disease":[89],"factors":[90,170,206,323,351],"were":[91,158,189,203,347],"significance":[94,265,353],"predicting":[96],"response":[97],"treatment.":[99],"This":[100],"large":[103],"sAML":[107,127,146,338,360],"variety":[114],"induction":[117,132,363],"regimens.":[118],"Materials":[119],"Methods:":[121],"Data":[122],"77":[124],"newly":[125,144,288],"diagnosed":[126,145,289],"at":[134,209],"Cleveland":[136],"Clinic":[137],"between":[138],"1997":[139],"2007":[141],"88":[143],"amonafide":[150],"+":[151],"cytarabine":[152],"combined.":[159],"The":[160,304],"focus":[161],"analysis":[164],"ascertain":[167],"affecting":[171],"overall":[172],"survival":[173],"(OS)":[174],"time":[176],"diagnosis.":[178],"Initially,":[179],"univariate":[180],"Cox":[181],"proportional":[182],"hazard":[183],"models":[184],"each":[186,294],"fitted.":[190],"Hazard":[191],"ratios":[192],"associated":[195],"95%":[196],"confidence":[197],"intervals":[198],"Wald":[200],"test":[201],"p-values":[202],"produced.":[204],"Prognostic":[205],"were:":[207],"age":[208,320,344],"diagnosis":[210],"(<60":[211],"years,":[212],"\u226560":[213],"years),":[214],"gender":[215,317,346],"(male,":[216],"female),":[217],"WBC":[218],"(<20":[219],"x109/L,":[220],"\u226520":[221],"x109/L),":[222],"peripheral":[223],"blasts":[224,229],"(<20%,":[225],"\u226520%),":[226],"bone":[227],"marrow":[228],"(<40%,":[230],"\u226540%),":[231],"cytogenetics":[232],"CALGB":[233],"class":[234,241],"(unfavorable,":[235],"intermediate,":[236],"favorable,":[237],"unknown),":[238],"secondary":[239],"disorder":[240],"tAML),":[243],"prior":[244,248],"(yes,":[246,250],"no),":[247],"radiotherapy":[249],"no).":[251],"Subsequently":[252],"multivariate":[254,306],"model":[255,307],"produced":[257],"using":[258],"stepwise":[260],"selection":[261],"method":[262],"level":[266],"5%,":[268],"having":[269],"imputed":[270],"missing":[271],"mean/median":[274],"values":[275],"as":[276,321,349],"appropriate.":[277],"Results:":[278],"In":[279,329],"165":[285],"sAML,":[290],"results":[292],"significant":[295],"are":[298],"outlined":[299],"table":[302,311],"below.":[303],"final":[305],"(displayed":[308],"below)":[312],"determined":[313],"unfavorable":[314],"cytogenetics,":[315,343],"male":[316],"advanced":[319],"predictive":[324],"worse":[326],"OS.":[327],"Conclusions:":[328],"178":[335],"22":[340],"US":[341],"centers,":[342],"identified":[348],"determining":[355],"outcome":[357],"treating":[359],"chemotherapy.":[364],"For":[365],"these":[368],"factors,":[370],"additional":[371],"therapeutic":[372],"strategies,":[373],"early":[375],"stem":[376],"cell":[377],"transplantation,":[378],"should":[379],"be":[380],"considered.":[381],"Disclosures:":[382],"Tejura:":[383],"Antisoma:":[384],"Employment.":[385],"Sekeres:":[386],"Celgene:":[387],"Honoraria,":[388],"Membership":[389],"on":[390],"an":[391],"entity's":[392],"Board":[393],"Directors":[395],"or":[396],"advisory":[397],"committees.":[398]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-11-30T00:00:00"}